Though a number of new drugs have become available for treating Type- 2 diabetes, sulphonyl ureas and biguanides still reign the scenario of 1 therapy. While either glibenclamide or glimepiride is the largely used sulphonyl urea derivative, metformin is the drug of choice from the biguanide group. Therefore a study on “Antidiabetic potentiality of newer oral antihyperglycemic combination therapy over conventional one” was carried out including 38 patients of type 2 diabetes mellitus receiving two varied types of combination therapy – one with glibenclamide and metformin and another with glimepiride and metformin. The aim of the study was to compare efficacy of these two combinations in the type 2 diabetic patients by monitoring Fasting Plasma Glucose (FPG) and Glycosylated Haemoglobin (HbA1c) for achieving good glycemic control and also to find out the effect of these two varied combination therapy on Lipid Profile & Body Mass Index (BMI). Male patients (65.79%) were observed to be more as compared to female patients (34.21%). People taking non-vegetarian (57.89%) were found more as compared to those taking vegetarian food (42.11%).Those patients having family history of diabetes (55.26%) were found more in the study group as compared to non diabetic family history (44.74%). The extent of diabetic control was determined by studying the fasting plasma glucose (FPG) content and the long term control by determining the glycosylated haemoglobin (HbA1c) level. At the end of study, the glimepiride combination therapy patients with 8% of HbA1c were 60.0 % as compared to glibenclamide combination therapy showing 39.13%. In the whole group of this study reduction in total and LDL cholesterol occurred significantly. But the reductions in the variables were relatively small in obese patients having higher BMI at baseline. Finally we concluded that combination therapy with metformin plus glimepiride(Group B) was found to be more effective than metformin plus glibenclamide(Group A) in improving glycemic control in type 2 diabetic patients.
KEY WORDS: Glycosylated Haemoglobin, Glycemic Control, Body Mass Index.